Sugi Predict

Sugi Predict / Compounds / SCHEMBL296731

SCHEMBL296731

SCHEMBL296731

COc1ccc(C[C@@H](OP(=O)(O)O)c2cc(OC)c(OC)c(OC)c2)cc1O

nearest known ligand 0.70

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TUBB1 Q9H4B7 10/20 0.64
▸ TUBB4A P04350 9/20 0.64
▸ TUBB P07437 9/20 0.64
▸ TUBA3C P0DPH7 9/20 0.64
▸ TUBA1B P68363 9/20 0.64
▸ TUBA4A P68366 9/20 0.64
▸ TUBB4B P68371 9/20 0.64
▸ TUBB3 Q13509 9/20 0.64
▸ TUBB2A Q13885 9/20 0.64
▸ TUBB8 Q3ZCM7 9/20 0.64
▸ TUBA3E Q6PEY2 9/20 0.64
▸ TUBA1A Q71U36 9/20 0.64
▸ TUBA1C Q9BQE3 9/20 0.64
▸ TUBB6 Q9BUF5 9/20 0.64
▸ TUBB2B Q9BVA1 9/20 0.64
▸ ALOX15 P16050 2/20 0.55
▸ ALOX12 P18054 2/20 0.55
▸ GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1508665 0.90 TUBB1 (0.58) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL19514765 0.89 TUBB1 (0.63) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL2856230 0.81 TUBB1 (0.66) TUBB1TUBB4ATUBBTUBA3CTUBA1B
Piperazine SCHEMBL1508698 0.81 TUBB1 (0.42) TUBB1TUBB4ATUBBTUBA3CTUBA1B
Combretastatin SCHEMBL19955 0.79 TUBB1 (1.00) TUBB1TUBB4ATUBBTUBA3CTUBA1B
Combretastatin SCHEMBL5566666 0.79 TUBB1 (1.00) TUBB1TUBB4ATUBBTUBA3CTUBA1B
Combretastatin SCHEMBL30334938 0.79 TUBB1 (1.00) TUBB1TUBB4ATUBBTUBA3CTUBA1B
Combretastatin SCHEMBL29356562 0.79 TUBB1 (1.00) TUBB1TUBB4ATUBBTUBA3CTUBA1B
Combretastatin SCHEMBL19956 0.79 TUBB1 (1.00) TUBB1TUBB4ATUBBTUBA3CTUBA1B
Combretastatin SCHEMBL29394501 0.79 TUBB1 (1.00) TUBB1TUBB4ATUBBTUBA3CTUBA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116287093-A Screening method of cell-embedded death agonist or antagonist and application thereof 无量光生物科技(鹤山市)有限公司 2023-06-23 — — CN claimed
EP-1179541-B1 Compositions and methods for cancer treatment by selectively inhibiting VEGF UNIV TEXAS (US) 2004-06-16 — — EP claimed
EP-1294405-A2 PRODRUG COMPOUNDS CLEAVABLE BY THIMET OLIGOPEPTIDASE CORIXA CORPORATION (US) 2003-03-26 — — EP claimed
JP-2002543093-A — — 2002-12-17 — — JP claimed
EP-1185559-A2 COMPOSITIONS AND METHODS FOR CANCER TREATMENT BY SELECTIVELY INHIBITING VEGF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-03-13 — — EP claimed
WO-2002015700-A1 PRODRUGS ACTIVATED BY PLASMIN AND THEIR USE IN CANCER CHEMOTHERAPY COULTER PHARMACEUTICAL, INC. (US) 2002-02-28 — — WO claimed
EP-1179541-A1 Compositions and methods for cancer treatment by selectively inhibiting VEGF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-02-13 — — EP claimed
WO-2001095945-A2 PRODRUG COMPOUNDS CLEAVABLE BY THIMET OLIGOPEPTIDASE MEDAREX, INC. (US) 2001-12-20 — — WO claimed
WO-2000064946-A2 COMPOSITIONS AND METHODS FOR CANCER TREATMENT BY SELECTIVELY INHIBITING VEGF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2000-11-02 — — WO claimed
EP-4385987-A1 IMPURITY IN PLINABULIN OR PREPARATION THEREOF, AND USE THEREOF Beyondspring Pharmaceuticals, Inc (US) 2024-06-19 — — EP disclosed
CN-117940418-A Impurities in plinabulin or its formulation and use thereof 大连万春布林医药有限公司 2024-04-26 — — CN disclosed
WO-2024078529-A1 PLINABULIN MICELLE COMPOSITION AND PREPARATION METHOD THEREFOR 大连万春布林医药有限公司 2024-04-18 — — WO disclosed
CN-117860672-A Plinabulin micelle composition and preparation method thereof 大连万春布林医药有限公司 2024-04-12 — — CN disclosed
US-20240041834-A1 PHARMACEUTICAL COMPOSITION ALEXION PHARMA INTERNATIONAL OPERATIONS LIMITED (IE) 2024-02-08 — — US disclosed
WO-2002012227-A2 INDOLE, AZAINDOLE AND INDAZOLE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY ASTRAZENECA AB (SE) 2002-02-14 — — WO disclosed
EP-1154774-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AstraZeneca AB (SE) 2001-11-21 — — EP disclosed
WO-2001077085-A1 QUINAZOLINE COMPOUNDS ASTRAZENECA AB (SE) 2001-10-18 — — WO disclosed
WO-2001066099-A2 USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2001-09-13 — — WO disclosed
WO-2001032651-A1 QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS ASTRAZENECA AB (SE) 2001-05-10 — — WO disclosed
WO-2000047212-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2000-08-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240041834-A1 PHARMACEUTICAL COMPOSITION CYP3A7, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, UGT2B7 TUBB1 731/4885TUBB4A 744/4885TUBB 647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.